Stefano Severi

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours

Stefano Severi, Oriana Nanni, Lisa Bodei et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 143 citations · Full text

Medicine, Nuclear Medicine, Oncology +12

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

Lisa Bodei, Mark Kidd, Irvin Modlin et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 143 citations

Medicine, Nuclear Medicine, Oncology +17

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

Lisa Bodei, Mark Kidd, Aviral Singh et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 131 citations

Medicine, Hematology, Pharmacology +8

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

Giovanni Paganelli, Maddalena Sansovini, A. Ambrosetti et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 122 citations

Medicine, Nuclear Medicine, Oncology +16

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

Maddalena Sansovini, Stefano Severi, Annarita Ianniello et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 121 citations

Medicine, Endocrinology, Nuclear Medicine +17